The American Society of Clinical Oncology (ASCO) will run a trial of its enrolling patients with advanced cancers but a dearth of standard treatment options. The trial will offer molecularly-targeted cancer drugs contributed free of charge by participating pharma companies.
The Targeted Agent and Profiling Utilization Registry (TAPUR) study will give “real-world” data on best uses of these drugs outside of approved indications.
ASCO petitioned several companies to sign on. Five major companies, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, and Pfizer, so far, have agreed to participate by signing memoranda of understanding.
